Exact Sciences of Madison, developer of a non-invasive stool-based test for colon cancer, is looking to sell another $200 million in stock to the public over the next three years. The company has filed a shelf registration that will allow it to sell shares in a streamlined fashion, though none will be sold in the immediate future.
Get Our Email Newsletter
The companies, people and issues shaping business in Madison and the Capital Region.
